. 2016 Jul 19;7(37):59482–59502. doi: 10.18632/oncotarget.10699

Table 2. The effect of PDTC treatment on the relationship between gastrocnemius mRNA expression and indices of cancer cachexia.

Gene expression	Cachexia Indices	Apc^Min/+
Gene expression	Cachexia Indices	R²	p value	R²	p value
SOCS3 mRNA	Body weight, sacrifice	0.33	0.06	0.08	0.38
	% BW change, peak to post	0.55	<0.01	0.36	0.05
	% BW, pre to post	0.79	<0.001	0.08	0.39
	Plasma IL-6	0.85	<0.001	0.71	<0.001
	GAS mass	0.41	0.03	0.43	0.03
	Spleen weight	0.57	<0.01	0.55	<0.01
IL-1β mRNA	Body weight, sacrifice	0.63	<0.01	0.11	0.31
	% BW change, peak to post	0.59	<0.01	0.12	0.30
	% BW, pre to post	0.53	0.01	0.12	0.30
	Plasma IL-6	0.59	<0.01	0.61	<0.01
	GAS mass	0.69	<0.01	0.22	0.14
	Spleen weight	0.70	<0.01	0.31	0.07

Pearson correlations were performed to determine the relationship between factors. C57BL/6 + PBS were included in each Apc^Min/+ treatment group analysis. Abbreviations: PBS, phosphate buffered saline. PDTC, pyrrolidine dithiocarbamate. BW, body weight. GAS, gastrocnemius. SOCS3, suppressor of cytokine signaling 3. IL-6, interleukin-6. IL-1β, interleukin-1β.